Abstract
Objective
Treatment beyond progression (TBP) with immune checkpoint inhibitors (ICIs) is an evolving field due to the limitations of conventional imaging in response evaluation. However, real-life data on the benefit of TBP is scarce, especially from the limited resource settings and patients treated in the later lines. Therefore, we aimed to investigate the survival benefit of TBP with ICIs in patients with advanced tumors from a limited resource setting.
Methods
For this multi-center retrospective cohort study, we included 282 patients treated with ICIs and had radiological progression according to RECIST 1.1 criteria. We evaluated post-progression survival according to the use of TBP (TBP and non-TBP groups) with univariate and multivariate analyses.
Results
The cohort’s median age was 61, and 84.4% were treated in the second or later lines. 82 (29.1%) of 282 patients continued on ICIs following the initial progression. In multivariate analyses, patients in the TBP group had improved post-progression survival compared to non-TBP (13.18 vs. 4.63 months, HR: 0.500, 95% CI: 0.349–0.717, p < 0.001). The benefit of the TBP was independent of the tumor type, treatment line, and age. Furthermore, TBP with ICIs remained associated with improved post-progression survival (HR: 0.600, 95% CI: 0.380–0.947, p = 0.028) after excluding the patients with no further treatment after progression in the non-TBP arm.
Conclusions
In this study, we observed that patients receiving ICIs beyond progression had considerably longer survival. Continuation of ICIs after progression should be considered a reasonable management option for patients with advanced cancer, specifically for patients with limited alternative options.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
All primary data are the responsibility of the authors, who agree to enable the journal to review it if required.
References
Beaver JA, Hazarika M, Mulkey F et al (2018) Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. Lancet Oncol 19(2):229–239. https://doi.org/10.1016/s1470-2045(17)30846-x
Benavente S, Sánchez-García A et al (2020) Therapy-Induced Modulation of the Tumor Microenvironment: New Opportunities for Cancer Therapies. Frontiers in Oncology. https://doi.org/10.3389/fonc.2020.582884
Bennouna J, Sastre J, Arnold D et al (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14(1):29–37. https://doi.org/10.1016/s1470-2045(12)70477-1
Borcoman E, Kanjanapan Y, Champiat S et al (2019) Novel patterns of response under immunotherapy. Ann Oncol 30(3):385–396. https://doi.org/10.1093/annonc/mdz003
Budimir N, Thomas GD, Dolina JS, Salek-Ardakani S (2022) Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade. Cancer Immunol Res 10(2):146–153. https://doi.org/10.1158/2326-6066.Cir-21-0515
Chen S, Zhang Z, Zheng X et al (2021) Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. Front Oncol. https://doi.org/10.3389/fonc.2021.562315
Czarnecka AM, Sobczuk P, Rogala P et al (2022) Efficacy of immunotherapy beyond RECIST progression in advanced melanoma: a real-world evidence. Cancer Immunol Immunother. https://doi.org/10.1007/s00262-021-03132-x
Dromain C, Beigelman C, Pozzessere C, Duran R, Digklia A (2020) Imaging of tumour response to immunotherapy. European Radiology Experimental 4(1):2–2. https://doi.org/10.1186/s41747-019-0134-1
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026
Emens LA, Ascierto PA, Darcy PK et al (2017) Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer 81:116–129. https://doi.org/10.1016/j.ejca.2017.01.035
Enomoto T, Tamiya A, Matsumoto K et al (2021) Nivolumab treatment beyond progressive disease in advanced non-small cell lung cancer. Clin Transl Oncol 23(3):582–590. https://doi.org/10.1007/s12094-020-02452-1
Escudier B, Motzer RJ, Sharma P et al (2017) Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. Eur Urol 72(3):368–376. https://doi.org/10.1016/j.eururo.2017.03.037
Esfahani K, Roudaia L, Buhlaiga N et al (2020) A review of cancer immunotherapy: from the past, to the present, to the future. Current Oncology(toronto, Ont). https://doi.org/10.3747/co.27.5223
Fujimoto D, Yoshioka H, Kataoka Y et al (2019) Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy. J Thorac Oncol 14(3):468–474. https://doi.org/10.1016/j.jtho.2018.10.167
Gandara DR, von Pawel J, Mazieres J et al (2018) Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study. J Thorac Oncol 13(12):1906–1918. https://doi.org/10.1016/j.jtho.2018.08.2027
Ge X, Zhang Z, Zhang S et al (2020) Immunotherapy beyond progression in patients with advanced non-small cell lung cancer. Translational Lung Cancer Research 9(6):2391–2400. https://doi.org/10.21037/tlcr-20-1252
George S, Motzer RJ, Hammers HJ et al (2016) Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial. JAMA Oncol 2(9):1179–1186. https://doi.org/10.1001/jamaoncol.2016.0775
Girard N, Jacoulet P, Gainet M et al (2009) Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice. J Thorac Oncol 4(12):1544–1549. https://doi.org/10.1097/JTO.0b013e3181bbf223
Goldinger SM, Buder-Bakhaya K, Lo SN et al (2022) Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. Eur J Cancer 162:22–33. https://doi.org/10.1016/j.ejca.2021.11.022
Gonzales Carazas MM, Pinto JA, Casado FL (2021) Biological bases of cancer immunotherapy. Expert Rev Mol Med 23:e3. https://doi.org/10.1017/erm.2021.5
Goto Y, Tanai C, Yoh K et al (2017) Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study. ESMO Open 2(4):e000214–e000214. https://doi.org/10.1136/esmoopen-2017-000214
Guven C, D., Sahin, T. K., Dizdar, O., & Kilickap, S. (2020) Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives. Biomark Med 14(14):1383–1392. https://doi.org/10.2217/bmm-2020-0310
Haddad R, Concha-Benavente F, Blumenschein G Jr et al (2019) Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. Cancer 125(18):3208–3218. https://doi.org/10.1002/cncr.32190
Haslam A, Prasad V (2019) Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Netw Open 2(5):e192535–e192535. https://doi.org/10.1001/jamanetworkopen.2019.2535
Iacovelli R, Ciccarese C, Facchini G et al (2020) Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. Target Oncol 15(4):495–501. https://doi.org/10.1007/s11523-020-00732-y
Jia W, Gao Q, Han A, Zhu H, Yu J (2019) The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. Cancer Biol Med 16(4):655–670. https://doi.org/10.20892/j.issn.2095-3941.2019.0144
Khoja L, Kibiro M, Metser U et al (2016) Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients. Br J Cancer 115(10):1186–1192. https://doi.org/10.1038/bjc.2016.308
Khozin S, Blumenthal GM, Pazdur R (2017) Real-world Data for Clinical Evidence Generation in Oncology. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djx187
Long GV, Weber JS, Larkin J et al (2017) Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. JAMA Oncol 3(11):1511–1519. https://doi.org/10.1001/jamaoncol.2017.1588
Luo J, Wu S, Rizvi H et al (2022) Deciphering radiological stable disease to immune checkpoint inhibitors. Ann Oncol. https://doi.org/10.1016/j.annonc.2022.04.450
Ma, Y., Wang, Q., Dong, Q., Zhan, L., & Zhang, J. (2019). How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy. American journal of cancer research, 9(8), 1546–1553. Retrieved from https://pubmed.ncbi.nlm.nih.gov/31497342
McDermott DF, Lee J-L, Bjarnason GA et al (2021) Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. J Clin Oncol 39(9):1020–1028. https://doi.org/10.1200/JCO.20.02363
Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456. https://doi.org/10.1016/s0140-6736(08)61039-9
Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 373(19):1803–1813. https://doi.org/10.1056/NEJMoa1510665
Nazha B, Yang JCH, Owonikoko TK (2020) Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer. Future Oncol 17(8):965–977. https://doi.org/10.2217/fon-2020-0951
Nishino M, Giobbie-Hurder A, Manos MP et al (2017) Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 23(16):4671–4679. https://doi.org/10.1158/1078-0432.CCR-17-0114
Park K, Yu CJ, Kim SW et al (2016) First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study. JAMA Oncol 2(3):305–312. https://doi.org/10.1001/jamaoncol.2015.4921
Ricciuti B, Genova C, Bassanelli M et al (2019) Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression. Clin Lung Cancer 20(3):178-185.e172. https://doi.org/10.1016/j.cllc.2019.02.001
Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. The Lancet 389(10066):255–265. https://doi.org/10.1016/S0140-6736(16)32517-X
Robert C, Long GV, Brady B et al (2014) Nivolumab in Previously Untreated Melanoma without BRAF Mutation. N Engl J Med 372(4):320–330. https://doi.org/10.1056/NEJMoa1412082
Schuler M, Yang JCH, Park K et al (2016) Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Ann Oncol 27(3):417–423. https://doi.org/10.1093/annonc/mdv597
Seymour L, Bogaerts J, Perrone A et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18(3):e143–e152. https://doi.org/10.1016/s1470-2045(17)30074-8
Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell 168(4):707–723. https://doi.org/10.1016/j.cell.2017.01.017
Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB (2020) Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers (basel). https://doi.org/10.3390/cancers12030738
Wang Z-X, Wu H-X, Xie L et al (2021) Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials. J Immunother Cancer 9(4):e002114. https://doi.org/10.1136/jitc-2020-002114
Yang J, Zhang Q, Wang J et al (2022) Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy. EBioMedicine. https://doi.org/10.1016/j.ebiom.2022.103958
Yu X, Chu X, Wu Y et al (2021) Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer. Cancer Drug Resistance (alhambra, Calif). 4(3):728–739
Funding
This research received no external funding.
Author information
Authors and Affiliations
Contributions
Conceptualization DCG, and SK, EY; data curation, EE, TKS, GK and SCY; formal analysis, DCG and EY; investigation, DCG, EY, SA, SY, YU; methodology, DCG, EY and SA; supervision, SK, SY, SA, DCG, ME, YU writing—original draft, DCG and EY; writing—review & editing, DCG, EE, SK, SY, SA, YU The published version of the work has been reviewed and approved by all authors.
Corresponding author
Ethics declarations
Conflicts of interest
The authors declare no conflict of interest.
Ethical approval
All techniques used in studies involving human subjects complied with the institutional and/or national research committee's ethical requirements, as well as the 1964 Helsinki statement and its subsequent revisions or similar ethical standards. The study was authorized by Istinye University's ethical committee.
Informed consent
Because of the study’s nature (retrospective cohort study), the need for informed consent was waived by the ethical committee.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Guven, D.C., Yekeduz, E., Erul, E. et al. The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study. J Cancer Res Clin Oncol 149, 3599–3606 (2023). https://doi.org/10.1007/s00432-022-04268-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-022-04268-8